Stelara 90 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FCRV4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $123,589
Award facts
- Contract value 100% obligated
- $123,588.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $123,588.96 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for Stelara 90 mg/mL syringes. The delivery order was issued on January 20, 2026, with an ultimate completion date of February 10, 2026, and carries no set-aside designation. This award was executed under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established on November 13, 2025, with a $499.999 billion ceiling value extending through December 31, 2036.
Stelara is a biologic immunosuppressant used to treat conditions including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. As a regional prime vendor contractor under the PPV-G GEN V program, DMS Pharmaceutical Group has been authorized to supply a comprehensive range of pharmaceutical products and medical consumables to support Department of Defense healthcare operations globally. The company's established performance history demonstrates its capability to deliver specialized pharmaceutical requirements to military healthcare facilities, with delivery orders historically ranging from under $100 to over $115,000 across multiple therapeutic categories including oncology treatments, biologics, vaccines, and routine pharmaceuticals.
Quick answers
Who was awarded contract SPE2DR26FCRV4?
SPE2DR26FCRV4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 20, 2026.
How much is contract SPE2DR26FCRV4 worth?
The government has obligated $123,589 on SPE2DR26FCRV4.
Is contract SPE2DR26FCRV4 an order under another contract?
Yes. SPE2DR26FCRV4 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRV4 competed?
The extent of competition for SPE2DR26FCRV4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award